Month December 2024

Cellectar refocuses on strong tumor radiotherapies

FLORHAM PARK, N.J. – Cellectar Biosciences, Inc. (NASDAQ: NASDAQ:CLRB), a small-cap biotech firm with a market capitalization of $52.62 million specializing in oncology, introduced at this time that it’s exploring strategic choices for the event and commercialization of its late-stage…

Revance agrees to decrease take-private supply by Crown Labs

(Reuters) -Crown Laboratories would purchase the anti-wrinkle injection maker Revance Therapeutics (NASDAQ:RVNC) at a roughly 50% lower cost in comparison with an unique settlement signed in August, the businesses mentioned on Monday, sending the latter’s inventory tumbling 20%. The lowered…